Tardive dyskinesia is a movement disorder that affects more than 573,000 adults in the United States. Three vesicular monoamine transporter 2 inhibitors have demonstrated the most promising evidence for the management of this challenging condition.
How To Treat
Although esketamine has been shown to be effective in the rapid reduction of suicidal ideation in patients who are at imminent risk of suicide, is a need for long-term safety studies and pharmacovigilance data, given the concerns of the potential for misuse and abuse.
Now that long-acting injectables are formulated with second-generation antipsychotics — including aripiprazole, olanzapine, paliperidone, and risperidone — which have fewer adverse effects than first-generation antipsychotics, emerging evidence has led psychiatrists to consider these agents for patients with a first episode of schizophrenia.